Eledon Pharmaceuticals (ELDN) Retained Earnings (2013 - 2026)

Eledon Pharmaceuticals has reported Retained Earnings for 14 years, with the latest figure at -$440.2 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 2445455.56% year-over-year to -$440.2 million; the trailing twelve-month figure through Mar 2026 stood at -$440.2 million (down 2445455.56% YoY), and the FY2025 full-year result was $24000.0, down 7.69% from the prior year.
• Retained Earnings for Q1 2026 stood at -$440.2 million, down from $24000.0 in the prior quarter.
• The five-year high for Retained Earnings was $102000.0 in Q3 2024, with the low at -$440.2 million in Q1 2026.
• Historically, Retained Earnings has averaged -$214.3 million across 5 years, with a median of -$213.6 million in 2023.
• Annual changes were most pronounced in 2024 — Retained Earnings jumped 100.04% — and 2026, when it slumped 2445455.56%.
• Eledon Pharmaceuticals' Retained Earnings stood at -$202.9 million in 2022, then slumped by 57.45% to -$319.4 million in 2023, then surged by 100.01% to $26000.0 in 2024, then slipped by 7.69% to $24000.0 in 2025, then slumped by 1834266.67% to -$440.2 million in 2026.
• The last three Retained Earnings figures came in at -$440.2 million (Q1 2026), $24000.0 (Q4 2025), and -$390.8 million (Q3 2025), per Business Quant data.